SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-042805
Filing Date
2024-05-14
Accepted
2024-05-14 13:53:33
Documents
74
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205836-10q_jasper.htm   iXBRL 10-Q 736871
2 CERTIFICATION ea020583601ex31-1_jasper.htm EX-31.1 13886
3 CERTIFICATION ea020583601ex31-2_jasper.htm EX-31.2 13683
4 CERTIFICATION ea020583601ex32-1_jasper.htm EX-32.1 6773
  Complete submission text file 0001213900-24-042805.txt   4777140

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20240331.xsd EX-101.SCH 56853
6 XBRL CALCULATION FILE jspr-20240331_cal.xml EX-101.CAL 40240
7 XBRL DEFINITION FILE jspr-20240331_def.xml EX-101.DEF 235970
8 XBRL LABEL FILE jspr-20240331_lab.xml EX-101.LAB 421219
9 XBRL PRESENTATION FILE jspr-20240331_pre.xml EX-101.PRE 233509
78 EXTRACTED XBRL INSTANCE DOCUMENT ea0205836-10q_jasper_htm.xml XML 496432
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 24942866
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)